Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lopinavir/ritonavir trial results ‘disappointing’ for severe COVID-19

Key clinical point: Treatment with lopinavir/ritonavir did not improve the clinical outcomes of patients with severe COVID-19.

Major finding: The median time to clinical improvement was 16 days in both groups (hazard ratio for lopinavir/ritonavir versus standard care, 1.31; 95% confidence interval, 0.95-1.85; P = .09).

Study details: A randomized, controlled, open-label trial of 199 adult patients hospitalized with laboratory confirmed SARS-CoV-2 infection.

Disclosures: The trial was supported by grants from Major Projects of National Science and Technology on New Drug Creation and Development and from the Chinese Academy of Medical Sciences (CAMS) Emergency Project of COVID-19, and a National Science Grant for Distinguished Young Scholars. All authors had no financial conflicts of interest to disclose.


Cao B et al. New Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282.